Maxonis is developing a peptide-hydrogel therapeutic that promotes nerve tissue regeneration following spinal cord injury (SCI) and peripheral nerve injury (PNI). Current treatment options for nerve repair are limited, invasive, and often yield poor functional recovery, leaving patients with few effective solutions. Maxonis’ off-the-shelf injectable hydrogel delivers the patented laminin-derived peptide LDP-916 to stimulate localized axonal growth and bridge nerve gaps, offering a simpler and safer alternative to graft and cell-based therapies. The venture’s patented platform and world-class leadership team, including pioneers in neuroreconstruction with multiple >$100M medtech exits, positions Maxonis to transform the standard of care for nerve repair.